Henry Schein Enters Into New Exclusive Distribution Agreement With CytoChip For Its CitoCBC System, FDA 510(K)-Cleared Device

Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S.

Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care.